Zydus Lifesciences Limited has informed the Exchange regarding a press release dated May 20, 2025, titled "Press release relating to audited financial results for the quarter and year ended on March 31, 2025.".
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Zydus Lifesciences reported strong FY25 results with consolidated revenue of Rs. 2,32,415 crore, up 19% year-on-year, and EBITDA of Rs. 70,585 crore, up 31% with margins expanding 290 basis points to 30.4%. Adjusted net profit for the year rose 23% to Rs. 47,451 crore, while reported net profit (after a Rs. 2,196 crore goodwill/technical know-how impairment) grew 17.3% to Rs. 45,255 crore. Q4 FY25 was particularly strong with revenue up 18% to Rs. 65,279 crore and EBITDA up 30% to Rs. 21,255 crore (32.6% margin). The US Formulations business, contributing 50% of revenue, grew 24% in Q4, while India Formulations grew 11% and Consumer Wellness surged 17%. The Board recommended a dividend of 1100% and the company ended the year with a net cash position of Rs. 48,836 crore.
Strong across-the-board growth with margin expansion, robust US business performance, and a healthy net cash balance sheet are positive for shareholders. The 1100% dividend recommendation signals confidence in cash flows, though the Rs. 2,196 crore impairment charge slightly dampens reported earnings.